Agios Pharmaceuticals Sees Unusually Large Options Volume (AGIO)

Agios Pharmaceuticals Inc (NASDAQ:AGIO) was the target of some unusual options trading activity on Thursday. Stock traders acquired 3,119 call options on the company. This represents an increase of approximately 1,790% compared to the average volume of 165 call options.

Agios Pharmaceuticals (NASDAQ:AGIO) opened at $75.11 on Friday. Agios Pharmaceuticals has a 12 month low of $39.24 and a 12 month high of $76.02. The stock has a market cap of $3,660.00, a price-to-earnings ratio of -11.98 and a beta of 1.83.

Agios Pharmaceuticals (NASDAQ:AGIO) last posted its earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($1.59) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.78) by $0.19. Agios Pharmaceuticals had a negative net margin of 506.39% and a negative return on equity of 69.64%. The business had revenue of $11.35 million for the quarter, compared to analyst estimates of $10.85 million. During the same period last year, the business posted ($1.63) EPS. Agios Pharmaceuticals’s revenue was up 26.4% compared to the same quarter last year. equities research analysts expect that Agios Pharmaceuticals will post -6.59 EPS for the current year.

In other news, insider Scott Biller sold 3,000 shares of the firm’s stock in a transaction on Wednesday, January 10th. The shares were sold at an average price of $65.00, for a total transaction of $195,000.00. Following the transaction, the insider now owns 56,059 shares in the company, valued at approximately $3,643,835. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO David P. Schenkein sold 6,000 shares of the firm’s stock in a transaction on Wednesday, November 1st. The shares were sold at an average price of $63.85, for a total transaction of $383,100.00. The disclosure for this sale can be found here. Insiders have sold a total of 32,130 shares of company stock worth $2,039,260 in the last 90 days. 5.43% of the stock is owned by insiders.

A number of hedge funds and other institutional investors have recently bought and sold shares of AGIO. FMR LLC grew its position in Agios Pharmaceuticals by 14.1% in the 2nd quarter. FMR LLC now owns 7,227,331 shares of the biopharmaceutical company’s stock worth $371,846,000 after purchasing an additional 895,584 shares during the last quarter. Vanguard Group Inc. grew its position in Agios Pharmaceuticals by 23.8% in the 2nd quarter. Vanguard Group Inc. now owns 3,214,770 shares of the biopharmaceutical company’s stock worth $165,401,000 after purchasing an additional 617,379 shares during the last quarter. BlackRock Inc. grew its position in Agios Pharmaceuticals by 23.5% in the 2nd quarter. BlackRock Inc. now owns 2,675,380 shares of the biopharmaceutical company’s stock worth $137,648,000 after purchasing an additional 508,306 shares during the last quarter. Alkeon Capital Management LLC acquired a new stake in Agios Pharmaceuticals in the 3rd quarter worth $30,489,000. Finally, Janus Henderson Group PLC acquired a new stake in Agios Pharmaceuticals in the 2nd quarter worth $20,423,000. Institutional investors own 93.79% of the company’s stock.

AGIO has been the topic of a number of recent research reports. Cann restated a “buy” rating on shares of Agios Pharmaceuticals in a report on Tuesday, December 5th. Oppenheimer set a $83.00 price target on shares of Agios Pharmaceuticals and gave the company a “buy” rating in a report on Friday, November 17th. BidaskClub downgraded shares of Agios Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Saturday, December 16th. SunTrust Banks set a $80.00 price target on shares of Agios Pharmaceuticals and gave the company a “buy” rating in a report on Sunday, November 19th. Finally, Credit Suisse Group raised their target price on shares of Agios Pharmaceuticals from $61.00 to $66.00 and gave the company an “outperform” rating in a research note on Thursday, November 2nd. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and twelve have issued a buy rating to the company. The stock has an average rating of “Buy” and an average price target of $75.00.

ILLEGAL ACTIVITY WARNING: “Agios Pharmaceuticals Sees Unusually Large Options Volume (AGIO)” was published by Stock Observer and is the sole property of of Stock Observer. If you are accessing this story on another domain, it was illegally stolen and republished in violation of US and international copyright & trademark law. The original version of this story can be accessed at https://www.thestockobserver.com/2018/01/14/agios-pharmaceuticals-sees-unusually-large-options-volume-agio.html.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.

Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply